Nykredit A S Takes $235.82 Million Position in Johnson & Johnson $JNJ

Key Points

• Nykredit A/S acquired 928,551 Johnson & Johnson shares worth approximately $235.8 million in the second quarter, making JNJ 0.7% of its portfolio and its 19th-largest holding. Institutional investors collectively own 69.55% of the company.
• Johnson & Johnson reported solid quarterly performance, with revenue up 6.6% year over year to $25.31 billion and EPS of $2.90, beating estimates. Analysts maintain a “Moderate Buy” consensus, with an average price target of $274.13.
• Positive lung-cancer trial results and continued underlying growth support the company’s outlook, while insiders sold $23.1 million of stock over the past three months. JNJ recently paid a quarterly dividend of $1.34, equivalent to a 2.0% annual yield.

Nykredit A S bought a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 928,551 shares of the company's stock, valued at approximately $235,824,000. Johnson & Johnson accounts for 0.7% of Nykredit A S's investment portfolio, making the stock its 19th biggest position.

Several other hedge funds have also recently bought and sold shares of the business. Silver Coast Investments LLC raised its position in Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company's stock valued at $271,000 after purchasing an additional 39 shares during the period. Townsend Asset Management Corp NC ADV boosted its position in shares of Johnson & Johnson by 0.6% in the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company's stock worth $1,630,000 after buying an additional 39 shares during the period. Triumph Capital Management grew its stake in shares of Johnson & Johnson by 1.6% in the second quarter. Triumph Capital Management now owns 2,531 shares of the company's stock valued at $643,000 after buying an additional 39 shares in the last quarter. Denali Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.2% during the 2nd quarter. Denali Advisors LLC now owns 3,305 shares of the company's stock valued at $839,000 after buying an additional 40 shares during the period. Finally, Beaird Harris Wealth Management LLC lifted its position in Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company's stock worth $501,000 after acquiring an additional 42 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Positive lung-cancer trial results: New data showed that RYBREVANT-based regimens improved survival outcomes in patients with EGFR-mutated non-small-cell lung cancer. The PAPILLON study reported the longest median overall survival yet reported for first-line treatment of EGFR exon 20 insertion disease, while the COPERNICUS study indicated improved tolerability and fewer treatment-related adverse events. These results strengthen the commercial outlook for JNJ’s oncology portfolio. Johnson & Johnson Reports Stronger Survival Data in EGFR-Mutated Lung Cancer
• Positive Sentiment: Defensive-investment appeal: Market commentary highlighted Johnson & Johnson as a defensive dividend stock with a strong balance sheet, rising payouts and share-repurchase potential. That positioning may attract investors amid ongoing Federal Reserve and inflation concerns. The September Scramble: Find Sanctuary in These 3 Defensive Dividend Stocks
• Positive Sentiment: Underlying growth remains solid: Despite declining Stelara sales, management has emphasized that underlying revenue growth remains healthy. Recent analysis noted that reported sales still increased 5.6% despite an approximately 460-basis-point Stelara drag, supporting the case that JNJ’s broader portfolio is gaining momentum. Should You Judge JNJ Stock Without Stelara?
• Neutral Sentiment: At the Deutsche Bank Healthcare Summit, JNJ presented its business outlook and strategy, but the available transcript listing did not identify a specific new announcement likely to materially change near-term valuation. Johnson & Johnson Presents at Deutsche Bank 2026 Healthcare Summit
• Negative Sentiment: JNJ’s gain trailed the broader market, suggesting that the session’s move was more defensive and company-specific than a sign of broad risk-taking. Its elevated valuation also leaves less room for disappointment if Stelara-related pressure persists.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Vanessa Broadhurst sold 23,054 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,779,963.81. The trade was a 50.06% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. The Goldman Sachs Group restated a "buy" rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. UBS Group began coverage on shares of Johnson & Johnson in a research report on Wednesday, September 2nd. They set a "buy" rating and a $320.00 target price on the stock. HSBC raised their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a "buy" rating in a report on Thursday, September 10th. Scotiabank reiterated an "outperform" rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Finally, TD Cowen upped their price objective on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a "buy" rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and a consensus price target of $274.13.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $270.65 on Friday. The firm has a market cap of $652.24 billion, a price-to-earnings ratio of 31.36, a PEG ratio of 2.55 and a beta of 0.24. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The business's 50 day moving average is $263.49 and its two-hundred day moving average is $246.55. Johnson & Johnson has a 52-week low of $173.33 and a 52-week high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. During the same quarter in the previous year, the firm earned $2.77 earnings per share. The business's revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Analysts forecast that Johnson & Johnson will post 11.61 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is 62.11%.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.